Seattle Genetics Win Early US FDA Approval For Tukysa, Plans Rapid Launch
Tucatinib, approved for advanced unresectable or metastatic HER2-positive breast cancer, has a list price of $18,500 per month or $111,000 for a full course. Doctors can order the drug immediately.
You may also be interested in...
The company provided updates on the timing of some data from its extensive clinical program for its KRAS G12C inhibitor Lumakras, but not for certain high-profile combinations.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.